CareFusion updates on annual report | Wall Street Beat Wall Street Beat

CareFusion (NYSE:CFN) said it’s done with most of its review of the accounting for its Pyxis medication dispensing line, which delayed the filing of its 4th-quarter and annual reports and prompted a warning from the New York Stock Exchange.

The medical device company said the accounting change shouldn’t affect its past financial statements and that it hopes to make the filings before Feb. 11, 2013.

"While restatement will continue to be a possibility until our analysis is complete, we have not identified any information that would lead us to conclude that our previously issued financial statements should no longer be relied upon or that the financial guidance we provided for fiscal 2013 should be changed," CFO James Hinrichs said in prepared remarks. "If at any time we determine a material misstatement exists, we would file a Form 8-K shortly thereafter announcing a restatement is required. At this point, our goal is to become current in all filings by our next deadline on Feb. 11, 2013. Clearly, we are working diligently to file sooner, if possible."

Sign up to get our free newsletters delivered straight to your inbox

In September, the NYSE warned CareFusion that it risked a delisting from the exchange unless it rectified the filing problem within 6 months. Two months later the company said it was still trying to resolve the issue as it issued preliminary Q1 numbers.

 Volcano details Crux buyout
Volcano (NSDQ:VOLC) said it paid out $3.1 million on top of the $36 million in cash it dropped on Crux Biomedical earlier this month to cover Crux’s expenses.

The San Diego-based medical device company also said it’s reserved some $3.9 million in escrow from the original payment "to indemnify Volcano and related indemnities for certain matters, including breaches of representations and warranties and covenants made by Crux in the merger agreement," according to a regulatory filing.

Volcano will shell out a $3 million milestone payment should the FDA grant 510(k) clearance for the Crux inferior vena cava filters for treatment of pulmonary embolisms before June 30, 2013. Additional payments over the ensuing 4 years are also possible, "based on commercial sales of Crux products (measured on a product-by-product basis) following commercial launch of the applicable product if such commercial launch occurs on or before Jan. 1, 2016 (for certain Crux products) or July 1, 2017 (for one of the Crux products and subject to extension in certain circumstances)," according to the filing.

"In the event that Volcano has not achieved the applicable commercial launch for one of the Crux products by June 30, 2016, (which date may be extended upon a specified payment by Volcano to June 30, 2017), Volcano will license back to the former Crux stockholders certain intellectual property rights relating to that product," Volcano said.
Read more

 Dynatronics announces 1-5 reverse split

Dynatronics (NSDQ:DYNT) said its shareholders approved a reverse split of its common stake, in which each 5 shares of stock convert into a single share, effective today.
Read more

 ACT spikes reverse split

Advanced Cell Technology (OTC:ACT) said it decided against a reverse stock split of its own, "primarily due to market conditions and other corporate factors."

"When we sought shareholder approval to complete such a move, we said that we would only pursue it if the market conditions were right, and a stock split would allow us to list on a national exchange. While listing on such an exchange remains a high priority, we believe the focus by our shareholders on a reverse split has contributed to a sharp decline in the price of our stock, despite the significant progress we have made in our clinical programs. We hope that by removing the reverse split from consideration at this time that investors will again focus on the potential of our technology and the promising results we have had in the clinic to date," chairman & CEO Gary Rabin said in prepared remarks.
Read more

 Computer Vision Systems raises $20M in debt offering
Computer Vision Systems (OTC:CVSL) landed $20 million in cash from Richmont Capital Partners in return for a convertible subordinated unsecured promissory note.
Read more

 Analysts’ ups and downs

  • C.R. Bard (NYSE:BCR): JMP Securities issues “outperform” rating, $118 price target.

RSS From Medical Design & Outsourcing

  • Emuge expands solid carbide thread mill program with new 3XD sizes
    Emuge is now offering an expanded line of Solid Carbide Thread Mills in their popular THREADS-ALL Program, to include new 3XD sizes designed for maximum reach. A total of 17 new sizes have been added, from miniature to standard size tools, providing maximum versatility in a wide range of thread milling applications. The 3XD THREADS-ALL […]
  • Start of helpful humanoid robots? CITEC uses compact LDS component as sensor array
    Editor’s Note: LaserMicronics, a service provider for laser-based manufacturing, has released the whitepaper “Robot hand with a sensitive touch: LDS tactile sensors for sensorimotor skills.” The paper describes a 2014 project from the CITEC department at Bielefeld University in Bielefeld, Germany, where researchers created a tactile sensor resembling a human fingertip. The sensor was then […]
  • Nature meets technology: Festo’s BionicANTs cooperate to solve a common task
    Editor’s Note: Festo, an industrial control and automation company, has released the whitepaper “BionicANTs: Cooperative behavior based on a natural model.” The paper describes the BionicANT, a creation of Festo engineers that duplicates the physical anatomy of its natural counterpart and reproduces the insect’s cooperative behavior. Festo engineers have used the delicate anatomy of an […]
  • Acorn Regulatory streamlines approval process drug-device manufacturers
    Acorn Regulatory, an ISO-certified medical device and pharmaceutical consulting firm, is streamlining procedures for U.S. manufacturers of drug-device combinations with customized programs that successfully overcome challenges in meeting European regulatory approvals. Focusing on small to mid-size companies, Acorn Regulatory has put in place a comprehensive step-by-step process that provides the correct regulatory pathway for medical […]
  • Athermal laser machining cuts bioabsorbable polymers and more
    A the recent MD&M East trade show in New York, Norman Noble, discussed the capability of athermal laser manufacturer. The company has developed the Noble S.T.E.A.L.T.H. (System To Enable Ablation Laser Technology Haz-free). The athermal laser machining process was developed to create precise features in any material, including bioabsorbable polymers, shape memory metals and other […]
  • Exciting possibilities for metallic glass in the medical device world
    Researchers are exploring the potential of metallic glass as a versatile, pliable material that is stronger than steel, with a bevy of possible medical device applications. Yale University engineers have discovered a unique method for designing metallic glass nanostructures across a wide range of chemicals, a technique that could have applications for everything from watch […]
  • Strong Precision Technologies’ medical divisions to unify under MedTorque brand
    Strong Precision Technologies announced on July 2, 2015, that its two medical divisions will now go to market under a single brand, MedTorque. The move reflects the increasing integration of the division formerly known as Inland Midwest with MedTorque, its sister division in Kenosha, WI. “We will continue providing our customers with the personalized level of service […]
  • Olympus offers next-day product replacement guarantee for medical devices
    Olympus, a medical and surgical procedures solutions company, announced that it is guaranteeing next-day replacements for surgical equipment at no additional charge. Olympus is the first surgical product manufacturer to offer this type of guarantee. The service became available to customers with an Olympus Full Service Agreement earlier this year. “Canceled procedures can be costly for healthcare facilities […]
  • More accurate prediction on prognosis in multiple myeloma from SkylineDx
    SkylineDx, a biotechnology company specializing in the development and commercialization of genetic tests, is launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the […]
  • Flint Mobile swaps card reader for camera, accept mobile payments anywhere
    Flint Mobile, the swipe-free mobile payments app, has significantly expanded its payment management and loyalty capabilities for small, service-centric businesses, like the ones run by on-the-go medical equipment professionals. The toggle-free mobile technology makes the process quite simple for both parties, as all transactions are conducted through the mobile device’s camera without the need of any external […]
  • Should scientists be allowed to genetically alter human embryos?
    Scientists have at their disposal, a way to explore the possible prevention of genetic diseases before birth. But should they? Currently, the most promising path forward involves editing the genes of human embryos, a procedure threaded with controversy. An article in “Chemical & Engineering News” (C&EN), the weekly newsmagazine of the American Chemical Society (ACS), parses […]

Leave a Reply